Heidelberg, Germany, March 24th 2022 – The Federal Republic of Germany has announced its decision to sign contracts with Celonic AG and...

Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment...

Heidelberg researchers are working on a rapid process for 3D imaging of cells Viral pathogens like the SARS-CoV-2 coronavirus change the...

The COVID-19 crisis that gripped England between September 2020 and June 2021 can be thought of as a series of overlapping epidemics,...

The Federal Ministry of Health (BMG) and the Federal Ministry of Education and Research (BMBF) are continuing to drive forward the joint...

Heidelberg research group seeks and develops inhibitors against flavi- and coronaviruses New drugs are intended to help stop viral...

What evolution has SARS-CoV-2 undergone since the beginning of the pandemic? Scientists from the German Cancer Research Center, in...

MASSIF-1, run jointly by EMBL Grenoble and the ESRF, is a beamline for macromolecular crystallography. It is used by the research...

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its...

• CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45...

The largest study of its type in the UK has identified differences in the immune response to COVID-19 in people with no symptoms,...

The first vaccines authorised for use are raising hopes for an end to the pandemic. What is still missing, however, is an effective ...

Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year More...

• CORAT Therapeutics antibody therapy obtained approval to start its clinical trial. • COR-101 is a human antibody that blocks virus...

Essential helpers to fight the coronavirus The antibody test developed in Reutlingen is sensitive and accurate. This is also confirmed...

Braunschweig , Nov 18, 2020. CORAT Therapeutics CEO Dr. Andreas Herrmann today announced the completion of the production campaign ofthe...

Dec. 4, 2020, Braunschweig, Germany – Because SARS-CoV-2 is a novel virus, many people have not yet developed antibodies against the...

YUMAB spin-off CORAT Therapeutics announced that the first major batch of its SARS-CoV-2 blocking antibody COR-101 has been produced and...

Innovation Award of the State of Lower Saxony for CORAT Consortium for the collaborative fast track development of COVID-19 antibodies....

We all hope that a COVID-19 vaccine is on the horizon - but the global cold chain must be prepared to distribute these vaccines around ...